Clinical Trials at New York Medical College
As of June 2026, 44 paid clinical trials are recruiting at New York Medical College, located at 15 DANA ROAD, BASIC SCIENCES BLDG ROOM C21, VALHALLA, NY 10595-1646, phone (914) 594-4730 in Valhalla, New York. Active studies at this site cover conditions such as Acute Myeloid Leukemia, ARDS and ARDS (Acute Respiratory Distress Syndrome). Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
44 clinical trials at New York Medical College
·Clear filters·↓ Download CSVA Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
CMV CTLs in Neonates With CMV Infection
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease
Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies
Project: Every Child for Younger Patients With Cancer
About research studies in Valhalla
Valhalla has approximately 107 recruiting research studies across a wide range of therapeutic areas. New York is home to leading academic medical centers such as Memorial Sloan Kettering, Weill Cornell Medicine, Mount Sinai, NYU Langone, and Columbia University Irving Medical Center. These institutions anchor a research ecosystem that covers oncology, cardiology, neurology, and rare disease.
Common conditions studied in Valhalla
- Acute Myeloid Leukemia (6 active studies). Leukemia trials evaluate targeted inhibitors, CAR-T cell therapies, and novel combinations for acute and chronic forms of the disease.
- ARDS (4 active studies). Recruiting ARDS studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- ARDS (Acute Respiratory Distress Syndrome) (4 active studies). Recruiting ARDS (Acute Respiratory Distress Syndrome) studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Respiratory Distress Syndrome (4 active studies). Recruiting Acute Respiratory Distress Syndrome studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Acute Respiratory Distress Syndrome (ARDS) (4 active studies). Recruiting Acute Respiratory Distress Syndrome (ARDS) studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Burkitt Lymphoma (4 active studies). Lymphoma research explores bispecific antibodies, CAR-T cell therapies, and new targeted agents for Hodgkin and non-Hodgkin lymphomas.
Leading research sponsors in Valhalla
- Children's Oncology Group
- New York Medical College
- National Cancer Institute (NCI)
- Merck Sharp & Dohme LLC
- PPD Development, LP
Local regulations and guidelines
Clinical trials in New York are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials conducted in New York must also comply with the NY SHIELD Act's data-protection requirements and additional oversight from the New York State Department of Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in Valhalla. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in Valhalla
Hipa.ai aggregates every recruiting study in Valhalla from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in Valhalla?
There are approximately 107 recruiting clinical trials in Valhalla, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Valhalla pay participants?
Most recruiting trials in Valhalla compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Valhalla?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Valhalla?
The most common conditions under active study in Valhalla include Acute Myeloid Leukemia (6), ARDS (4), ARDS (Acute Respiratory Distress Syndrome) (4), Acute Respiratory Distress Syndrome (4), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Valhalla?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Valhalla on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Valhalla?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Valhalla?
Recruiting research sites in Valhalla include New York Medical College, Westchester Medical Center, New York Medical College at Westchester Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Valhalla right now?
The largest active categories in Valhalla are Cancer & tumors (37), Cardiovascular (9), Neurology & pain (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of New York Medical College?
New York Medical College is located at 15 DANA ROAD, BASIC SCIENCES BLDG ROOM C21, VALHALLA, NY 10595-1646. Use the Google Maps link in the intro above to get directions.
How do I contact New York Medical College?
You can reach New York Medical College by phone at (914) 594-4730. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.